Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Inovio Pharmaceuticals
Thumbnail
April 20, 2022

Arcturus’s latecomer Covid vaccine elicits little interest

Thumbnail
November 17, 2021

Atea’s woes grow while other Covid readouts approach

Big upcoming events include data from a trial of Pfizer’s oral antiviral Paxlovid in patients at risk of severe illness.

Article image
Vantage logo
September 03, 2021

No let-up in Covid-19 vaccine trials

A project from SK Bioscience and Glaxo started phase 3 this week, but it is far from the only late-stage candidate.

Article image
Vantage logo
May 19, 2021

Glaxo’s Covid-19 effort progresses, this time thanks to Medicago

Article image
Vantage logo
May 11, 2021

Covid-19 vaccine leaders make hay while Novavax flounders

Instead of long-awaited phase 3 data Novavax’s first-quarter presentation reveals a Covid-19 vaccine manufacturing snafu.

Article image
Vantage logo
April 22, 2021

Valneva joins the phase 3 Covid-19 vaccine club

Meanwhile, Ocugen hopes that Covaxin's India data will be enough for US approval.

Article image
Vantage logo
March 02, 2021

Inovio’s reinvention falls flat

The company’s claims of a win with its cervical precancer therapy candidate look questionable.

Article image
Vantage logo
February 01, 2021

Covid-19 vaccine pipeline builds as Clover and Dynavax push on

Article image
Vantage logo
December 31, 2020

Clinical developments over the Christmas period

Trial results in Covid-19 and cancer emerge, but little promise is seen.

Article image
Vantage logo
October 22, 2020

The growing exposure to novel Covid-19 treatments

Article image
Vantage logo
October 13, 2020

J&J pause adds to adenovirus vaccine doubts

Details are scant about the “unexplained illness” seen with Johnson & Johnson’s Covid-19 vaccine, but the news puts another dent in public confidence.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

June 16, 2022

Vantage Top 10 Most Read Report

June 15, 2022

Asco 2022 eBook

View more...

Editor's Picks

Vantage logo
June 14, 2022

Roche deal fails to Repare the licensing scene

Vantage logo
June 13, 2022

EHA 2022 – Crispr still looks bloody good

Vantage logo
June 05, 2022

Asco 2022 – Enhertu asks, how low can you go?

Vantage logo
June 09, 2022

Asco 2022 movers – cell therapy wins, but it’s not the whole story

Vantage logo
May 30, 2022

Abbvie to become the biggest of pharmas in 2028

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.